Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 859M 763M 707M 644M 1.21B 81.5B 1.23B 8.5B 3.33B 42.53B 3.22B 3.15B 136B P/E 2026 *
14.7x
P/E 2027 * 11.8x
Enterprise Value 859M 763M 707M 644M 1.21B 81.5B 1.23B 8.5B 3.33B 42.53B 3.22B 3.15B 136B EV / Sales 2026 *
2.81x
EV / Sales 2027 * 2.3x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day-2.71%
1 week-6.34%
Current month-4.53%
1 month-1.44%
3 months+13.39%
6 months+41.75%
Current year+7.33%
1 week 45.68
Extreme 45.68
48.87
1 month 45.22
Extreme 45.22
50.49
Current year 24.95
Extreme 24.95
50.49
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 21/11/2014
Director of Finance/CFO 63 29/05/2018
Compliance Officer 58 01/12/2022
Director TitleAgeSince
Director/Board Member 71 01/03/1997
Director/Board Member 65 21/11/2014
Chairman 67 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Exercice

Chief Financial Officer

9,200 0.0493%
9/1/26 A Tax

Compliance Officer

-877 0.0047%
9/1/26 A Tax

Chief Executive Officer

-2,424 0.0130%
Change 5-day change 1-year change 3-year change Capi.($)
-2.71%-6.34%+64.53%+384.25% 859M
+0.43%+6.59%+56.57%+107.01% 1,120B
+0.90%-2.25%+32.26%+67.33% 616B
+0.71%+3.24%+24.33%+91.20% 504B
-0.13%+5.98%+33.66%+52.01% 367B
+0.52%+0.24%+72.13%+43.10% 360B
-0.95%+4.70%+19.65%+43.09% 288B
-1.98%+3.73%-0.89%+17.28% 258B
-0.35%+4.25%+44.74%+52.51% 234B
-0.75%+3.32%+27.18%+96.05% 194B
Average -0.43%+2.35%+37.42%+95.38% 394.18B
Weighted average by Cap. +0.13%+3.52%+39.34%+73.58%

Financials

2026 *2027 *
Net sales 306M 272M 252M 229M 432M 29.02B 439M 3.03B 1.19B 15.14B 1.15B 1.12B 48.27B 373M 331M 307M 279M 527M 35.38B 536M 3.69B 1.45B 18.47B 1.4B 1.37B 58.86B
Net income 61.66M 54.81M 50.8M 46.22M 87.22M 5.85B 88.61M 611M 239M 3.05B 231M 226M 9.73B 81.45M 72.4M 67.1M 61.05M 115M 7.73B 117M 807M 316M 4.03B 306M 299M 12.86B
Net Debt - -
Projected Income Statement - Annual - Rigel Pharmaceuticals, Inc.
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
16/10/26 $45.97 -2.71% 141,432
15/10/26 $47.25 +0.92% 167,854
14/10/26 $46.82 -0.68% 160,104
13/10/26 $47.14 -3.42% 133,999
12/10/26 $48.81 -0.55% 162,529
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rigel Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
45.97USD
Average target price
63.00USD
Spread / Average Target
+37.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rigel Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. RIGL Stock